Opus Genetics Reports Strong Q2 Progress with Multiple Clinical Milestones and Expanded Gene Therapy Pipeline

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule treatments for other ophthalmic disorders, announced second quarter 2025 financial results alongside a series of significant clinical and regulatory achievements.

CEO Dr. George Magrath described the quarter as a period of pivotal progress, emphasizing the U.S. Food and Drug Administration's Regenerative Medicine Advanced Therapy (RMAT) designation for the company's lead program, OPGx-LCA5, as a key milestone. He noted that the designation underscored the strength of the clinical data and the urgent need for effective treatments for IRDs. Twelve-month data from the adult cohort in the Phase 1/2 trial showed sustained visual acuity gains and improved mobility scores, while early pediatric results at one month post-treatment demonstrated vision improvements without drug-related adverse events. Three-month pediatric data are expected in the third quarter of 2025.

Opus also advanced OPGx-BEST1 toward the clinic, with preclinical results demonstrating restoration of the retinal pigment epithelium-photoreceptor interface in canine models. The company remains on track to submit an Investigational New Drug (IND) application and initiate a Phase 1/2 trial in the second half of the year. Additional programs, including OPGx-RDH12 and OPGx-MERTK, progressed with the support of up to $1.6 million in non-dilutive funding from the Global RDH12 Alliance and up to $2 million from the Retinal Degeneration Fund. Preclinical data for OPGx-MERTK presented earlier this year showed preservation of retinal function in animal models.

Beyond gene therapy, Opus reported strong late-stage results for its small molecule program, Phentolamine Ophthalmic Solution 0.75%. The VEGA-3 Phase 3 trial in presbyopia met its primary and multiple secondary endpoints, with more than a quarter of treated patients achieving significant near visual acuity improvements compared to placebo, alongside favorable safety and patient-reported outcomes. The LYNX-2 Phase 3 trial in keratorefractive patients with night vision disturbances also met its primary and secondary endpoints, showing statistically significant gains in low-light contrast vision and reductions in night-driving related symptoms. The company plans to submit a supplemental New Drug Application (sNDA) for the presbyopia indication in the second half of 2025 and to initiate the LYNX-3 Phase 3 trial later this year to target reduced low-light vision and nighttime visual disturbances.

Financially, Opus ended the quarter with $32.4 million in cash and cash equivalents, which is expected to fund operations into the second half of 2026. License and collaboration revenue totaled $2.9 million, up from $1.1 million in the prior year period, largely from its collaboration with Viatris, Inc. General and administrative expenses rose to $5.8 million from $3.4 million a year earlier, reflecting higher legal, payroll, and business development costs, while research and development expenses were $6.0 million compared to $6.1 million last year, with increased clinical trial and payroll-related expenses offset by lower manufacturing and consulting costs. Net loss for the quarter was $7.4 million, or $(0.12) per share, compared to a net loss of $7.8 million, or $(0.30) per share, in the same period of 2024.

With multiple programs advancing toward pivotal stages, strong clinical results, and external funding support for early-stage assets, Opus Genetics enters the second half of 2025 focused on key regulatory filings, new trial initiations, and continued execution toward delivering transformative therapies for patients with significant unmet vision needs.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company's pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/

The post Opus Genetics Reports Strong Q2 Progress with Multiple Clinical Milestones and Expanded Gene Therapy Pipeline appeared first on PRISM MarketView.

COMTEX_468036762/2927/2025-08-14T12:01:35